Trial reportBlood advances2026
A specific FX activator for bleeding treatment in hemophilia with inhibitors: multicenter, open-label, phase 1/2 trials.
Trial report in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase Ib/II,Multi-center, Open, Multiple-dose Design to Evaluate the Safety,Tolerability and Efficacy of STSP-0601 for Injection in Patients With Inhibitory Hemophilia
A Multi-center, Open-label, Phase Ⅱb Trial to Evaluate the Safety and Efficacy of STSP-0601 for Injection in Patients with Hemophilia with Inhibitor
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractBemiltenase alfa, a factor X (FX) activator derived from Daboia russelii siamensis venom, was developed as a hemostatic agent for hemophilia A and B with inhibitors (HAwI and HBwI). We conducted 2 consecutives multicenter, open-label clinical trials. The phase 1b/2a study assessed the safety, hemostatic efficacy, and pharmacokinetic/pharmacodynamic characteristics of bemiltenase alfa at a dose of 0.1 U/kg. The phase 2b study further evaluated the safety and efficacy at a dose of 0.1 U/kg. Primary efficacy end points encompassed the effective hemostasis rate, safety assessment, and antidrug antibody (ADA) development. There were 6 participants enrolled in the phase 1b study, 20 in phase 2a, and 25 in phase 2b. Patients received bemiltenase alfa for bleeding episodes in the phase 2a and 2b studies. In phase 2a, the effective hemostasis rate was 94.1% (95% confidence interval [CI], 88.7-97.4). Phase 2b showed a rate of 81.9% (95% CI, 71.0-92.9). Most adverse events were mild with grade 1 severity, with no serious events. ADA was detected in 5 patients, but no impact on efficacy and safety was found. Pharmacokinetic findings showed repeated doses of bemiltenase alfa resulted in progressive drug concentration, as indicated by the accumulation ratio index. Pharmacodynamic results indicated a reduction in activated partial thromboplastin time and an increase in thrombin generation peak. Furthermore, a mild decline in FX activity was observed postadministration. The study demonstrates FX activation as a novel hemostatic strategy, with snake venom-derived bemiltenase alfa showing promising safety and efficacy for treating bleeding episodes in patients with HAwI and HBwI. These trials were registered at www.clinicaltrials.gov as #NCT05027230 and #NCT06289166.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.